Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, and other mature T-cell lymphomas, will be featured in three poster presentations at the American Society of Hematology (ASH) 2025 annual meeting in Orlando, FL. The presentations will include new findings on mogamu ...